UY31057A1 - Formulaciones de aminoacido n-halogenado que contiene acido alifatico - Google Patents

Formulaciones de aminoacido n-halogenado que contiene acido alifatico

Info

Publication number
UY31057A1
UY31057A1 UY31057A UY31057A UY31057A1 UY 31057 A1 UY31057 A1 UY 31057A1 UY 31057 A UY31057 A UY 31057A UY 31057 A UY31057 A UY 31057A UY 31057 A1 UY31057 A1 UY 31057A1
Authority
UY
Uruguay
Prior art keywords
acid
amino acid
alifatic
halogenated amino
formulations containing
Prior art date
Application number
UY31057A
Other languages
English (en)
Spanish (es)
Inventor
Han Wesley Wehsin
Masood A Chowhan
Larry Wayane Schneider
David W Stroman
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of UY31057A1 publication Critical patent/UY31057A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Eyeglasses (AREA)
UY31057A 2007-05-01 2008-04-29 Formulaciones de aminoacido n-halogenado que contiene acido alifatico UY31057A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91527107P 2007-05-01 2007-05-01

Publications (1)

Publication Number Publication Date
UY31057A1 true UY31057A1 (es) 2008-10-31

Family

ID=39616420

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31057A UY31057A1 (es) 2007-05-01 2008-04-29 Formulaciones de aminoacido n-halogenado que contiene acido alifatico

Country Status (17)

Country Link
US (2) US20080275126A1 (enExample)
EP (1) EP2139520B1 (enExample)
JP (2) JP2010526084A (enExample)
KR (1) KR20100017156A (enExample)
CN (1) CN101678105A (enExample)
AR (1) AR066371A1 (enExample)
AU (1) AU2008245460B2 (enExample)
BR (1) BRPI0811073A2 (enExample)
CA (1) CA2684101A1 (enExample)
CL (1) CL2008001283A1 (enExample)
ES (1) ES2432408T3 (enExample)
MX (1) MX2009011817A (enExample)
RU (1) RU2009144291A (enExample)
TW (1) TW200902092A (enExample)
UY (1) UY31057A1 (enExample)
WO (1) WO2008134692A1 (enExample)
ZA (1) ZA200907052B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2265267B1 (en) * 2008-04-10 2016-09-21 Waldemar Gottardi Compositions comprising n-halogenated or n, n-dihalogenated amine for treatment and prophylaxis of bronchopulmonary infections
WO2009127924A1 (en) * 2008-04-15 2009-10-22 Waldemar Gottardi Compositions and devices for antisepsis and anticoagulation
CN113729039A (zh) * 2021-08-27 2021-12-03 上海罗克环控节能科技股份有限公司 一种绿色环保消毒液及其制造方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6027965B2 (ja) * 1980-02-23 1985-07-02 東洋コンタクトレンズ株式会社 コンタクトレンズに付着した汚れの除去方法
US5421818A (en) * 1993-10-18 1995-06-06 Inner Ear Medical Delivery Systems, Inc. Multi-functional inner ear treatment and diagnostic system
AU3070395A (en) * 1994-07-22 1996-02-22 Alcon Laboratories, Inc. Use of low molecular weight amino acids in ophthalmic compositions
US6156728A (en) * 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
US6387427B1 (en) * 2000-09-28 2002-05-14 Nestec S.A. Method of preservation of a food product
WO2003061566A2 (en) * 2002-01-24 2003-07-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anti-cancer combination and use thereof
PL1656095T3 (pl) * 2003-08-18 2014-04-30 Novabay Pharmaceuticals Inc N,n-dwuchlorowcowane kwasy aminowe i pochodne
TWI386201B (zh) * 2005-01-25 2013-02-21 Novabay Pharmaceuticals Inc Ｎ-鹵化胺基酸、ｎ，ｎ-二鹵化胺基酸與其衍生物；以及使用其之組合物與方法
TWI432231B (zh) * 2005-10-06 2014-04-01 Novabay Pharmaceuticals Inc 使用ｎ-鹵化胺基酸於預防包括泌尿道感染（ｕｔｉ）之細菌性與真菌性感染的系統與方法

Also Published As

Publication number Publication date
CA2684101A1 (en) 2008-11-06
BRPI0811073A2 (pt) 2014-12-09
KR20100017156A (ko) 2010-02-16
MX2009011817A (es) 2009-11-13
TW200902092A (en) 2009-01-16
CN101678105A (zh) 2010-03-24
RU2009144291A (ru) 2011-06-10
JP2010526084A (ja) 2010-07-29
WO2008134692A1 (en) 2008-11-06
ES2432408T3 (es) 2013-12-03
EP2139520B1 (en) 2013-08-21
ZA200907052B (en) 2010-12-29
EP2139520A1 (en) 2010-01-06
AR066371A1 (es) 2009-08-12
JP2014098037A (ja) 2014-05-29
US20080275126A1 (en) 2008-11-06
AU2008245460B2 (en) 2013-08-22
CL2008001283A1 (es) 2009-01-16
US20110060044A1 (en) 2011-03-10
AU2008245460A1 (en) 2008-11-06

Similar Documents

Publication Publication Date Title
CO6821938A2 (es) Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1
CY1118601T1 (el) Αλκυλαμινο-υποκατεστημενες δικυανοπυριδινες και προφαρμακα τυπου εστερα αμινοξεος αυτων
AR081681A1 (es) METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA
UY33694A (es) ?inhibidores de n1/n2-lactama acetil-coa carboxilasa?.
CR20120190A (es) INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA
GT201200276A (es) Combinaciones de compuestos activos
UY30762A1 (es) Sal fumarato de (alfa s, beta r)-6-bromo-alfa-[2(dimetilamino) etil]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol
EA201390339A1 (ru) Замещенные имидазопиридазины
CR20130464A (es) Inhibidores sustituidos de acetil-coa carboxilasa
BR112013020767A2 (pt) composições compreendendo ácido peróxi alfa-cetocarboxílico e métodos para a produção e o uso do mesmo
AR081611A1 (es) Combinaciones de principios activos acaricidas y/o insecticidas
BR112012007798A2 (pt) microcápsulas estáveis e composição para aplicação tópica e método para a preparação de microcápsulas
MX2010007670A (es) Uso de sal de acido acetilsalicilico para tratamiento de infecciones virales.
UY31788A (es) Formulación farmacéutica sólida con liberación retardada
EA201201239A1 (ru) Композиция, содержащая в качестве активного ингредиента l-карнитин в комбинации с гидроксикинуренин-о-бета-dl-глюкозидом, для предотвращения и/или лечения патологий глаза, вызванных ультрафиолетовым излучением
CO6551731A2 (es) Composiciòn de combinaciòn que comprende como ingrediente activo l- carnitina o propionil l- carnitina, para la prevenciòn o tratamiento de insuficienca venosa crònica
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
CR20120521A (es) Combinaciones de principios activos
UY31059A1 (es) Formulaciones de aminoacido n-halogenado
CO6382113A2 (es) Compuestos quimicos
CR20110022A (es) Nuevas posibilidades de lucha contra la giardiasis
UY31058A1 (es) Formulaciones de aminoacido n-halogenado con compuestos antiinflamatorios
UY31057A1 (es) Formulaciones de aminoacido n-halogenado que contiene acido alifatico
BR112014011315B8 (pt) uso de um composto como agente terapêutico para artrose
CL2008001280A1 (es) Composicion farmaceutica que comprende una sal de aminoacido n-halogenado; procedimiento de preparacion; y su uso como antimicrobiano.